Show simple item record

dc.contributor.authorSeidi, K
dc.contributor.authorJahanban-Esfahlan, R
dc.date.accessioned2018-08-26T08:32:31Z
dc.date.available2018-08-26T08:32:31Z
dc.date.issued2013
dc.identifier.urihttp://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/52302
dc.description.abstractTuberculosis (TB) is a growing unsolved health concern, as it is the main infectious cause of death in the globe. The ability of the pathogen to develop into a dormant state is the main obstacle in overcoming the disease. It seems that the development of compounds that can target latent TB is the key to eradicate this pathogen. In this regard, many researchers started to search for novel compounds that could inhibit the activity of molecules involved in the resuscitation of latent bacilli. The discovery of an extremely potent anti-dormancy factor, a resuscitation-promoting factor (Rpf) from Micrococcus luteus, shifted the idea towards developing potent inhibitors of Rpfs to establish latent TB and avoid reactivation of the sleeping pathogen. However, besides the advantages of this approach over the application of annoying long-term regimes of toxic antibiotics, such approaches that rely on silencing latent TB have many drawbacks that may question their application in human research. The major drawback of the current approaches is that they hide the latent TB rather than treating/eradicating it. Here, we propose a novel cost-effective approach that could effectively eradicate both active and latent TB in a short period of time without having any risk of reactivation. é 2013 Tehran University of Medical Sciences.
dc.language.isoEnglish
dc.relation.ispartofJournal of Medical Hypotheses and Ideas
dc.subject2 nitrophenylthiocyanate
dc.subjectantibiotic agent
dc.subjectbenzimidazole
dc.subjectCD39 antigen
dc.subjectenoyl acyl carrier protein reductase (NADPH)
dc.subjectmonoclonal antibody
dc.subjectMycobacterium vaccine
dc.subjectnitrotriazole
dc.subjectresuscitation promoting factor B vaccine
dc.subjectresuscitation promoting factor vaccine
dc.subjectstem cell factor receptor
dc.subjecttuberculostatic agent
dc.subjectunclassified drug
dc.subjectantibiotic resistance
dc.subjectarticle
dc.subjectbacterial strain
dc.subjectcomparative study
dc.subjectcost effectiveness analysis
dc.subjectdrug cost
dc.subjectdrug efficacy
dc.subjectdrug potency
dc.subjectdrug safety
dc.subjectdrug targeting
dc.subjecthuman
dc.subjectimmunogenicity
dc.subjectin vitro study
dc.subjectin vivo study
dc.subjectinfection risk
dc.subjectlatent tuberculosis
dc.subjectMicrococcus luteus
dc.subjectmolecular weight
dc.subjectnonhuman
dc.subjectpostprimary tuberculosis
dc.subjecttreatment duration
dc.subjecttuberculosis
dc.subjecttuberculosis control
dc.titleA novel approach to eradicate latent TB: Based on resuscitation promoting factors
dc.typeArticle
dc.citation.volume7
dc.citation.issue2
dc.citation.spage69
dc.citation.epage74
dc.citation.indexScopus
dc.identifier.DOIhttps://doi.org/10.1016/j.jmhi.2013.04.002


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record